Alexion Skids as Muscle Drug Trial Fails to Meet Primary GoalBy and
Shares fall the most since 2010 as results disappoint
Drug for muscle disease didn’t lead to activity improvements
Alexion Pharmaceuticals Inc. fell the most in six years after the company’s drug for a rare neuromuscular disease failed to meet its primary goal in a final-stage trial.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.